Reported Sunday, Rigel Presents Updated Phase 1b R289 Data In Lower-Risk MDS At ASH 2025, Showing 33% RBC-TI At ≥500 Mg With Favorable Tolerability
Benzinga Newsdesk 11 months ago
News
R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patientsRBC-TI was achieved by 33% (6/18) of evaluable transfusion
- R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients
- RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group